Medicare’s restrictive coverage policies are denying patients with early Alzheimer’s disease access to novel treatments. And private payers are following suit.
American Medical Association president responds to AAPA letters calling for dialogue on AMA’s ‘scope creep’ campaign against expanding practice for other clinicians.